Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,455.50 +269.72 (+0.42%) CMC Crypto 200
1,351.86 -8.47 (-0.62%)
REGN Nov 2024 820.000 put
- Zacks
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
- GlobeNewswire
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
- Simply Wall St.
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
